Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aitua Combination Antibody + Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
NCT07432594Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iparomlimab + tuvonralimab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Rate of R0 resection at 12 weeks. Started Jul 2026; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07432594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07432594.